BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 23, 2017
View Archived Issues
Pan-CK2 inhibitor BMS-159 chosen for development as anticancer candidate
Read More
IdeS reduces donor-specific antibodies allowing for HLA-incompatible transplantation
Read More
Genentech presents data from phase I trial of influenza B candidate MHAB-5553A
Read More
BMP inhibition a novel pharmacological strategy for multiple hereditary exostoses
Read More
Trisubstituted benzene CGRP antagonists for migraine created at Merck & Co.
Read More
PharmAkea completes phase I study of PAT-1251
Read More
New phase IIa trial tests S. hominis lotion for atopic dermatitis
Read More
Sun Pharma Advanced Research discovers novel Bruton tyrosine kinase inhibitors
Read More
Pharmakea presents new lysyl oxidase homolog 2 inhibitors
Read More
Takeda submits Japanese NDA for vedolizumab for ulcerative colitis
Read More
FDA grants orphan drug designation to Jotrol for Friedreich's ataxia
Read More
CIRM grant supports Cellerant's development of CLT030-ADC for AML
Read More
Phase Ib results reported for proinsulin peptide immunotherapy in subjects with type 1 diabetes
Read More
AC Immune expands neurodegenerative pipeline with new antibodies against alpha-synuclein and TDP-43
Read More
Topas signs research and option agreement with Lilly focused on antigen-specific tolerance induction
Read More
Janssen describes synthesis of GPR40 full agonists for type 2 diabetes
Read More
CRISPR Therapeutics and Massachusetts General Hospital collaborate to develop T-cell therapies
Read More
Obesity compounds begin phase I trials under Zealand and Boehringer Ingelheim collaboration
Read More
Phase III study of Ace-ER in GNE myopathy misses primary endpoint
Read More